INAB
In8bio Inc
NASDAQ: INAB · HEALTHCARE · BIOTECHNOLOGY
$1.47
-2.65% today
Updated 2026-04-30
Market cap
$15.36M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.44
Dividend yield
—
52W range
$1 – $6
Volume
0.1M
WallStSmart proprietary scores
29
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.0
Quality
C+3.0
Profitability
D5.0
Valuation
C+—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$6.25
+325.17%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
Insufficient data
Risks
- Thin margins at 0.00%
- Negative free cash flow $-2.14M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-27.42M | $-30.01M | $-30.44M | $-19.44M | $-4.94M |
| EPS | — | — | — | — | $-4.44 |
| Free cash flow | $-27.83M | $-23.94M | $-24.25M | $-12.71M | $-2.14M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
In8bio Inc trades at $1.47. Our Smart Value Score of 29/100 indicates the stock is weak.
Frequently asked questions
What is In8bio Inc's stock price?
In8bio Inc (INAB) trades at $1.47.
Is In8bio Inc overvalued?
Smart Value Score 29/100 (Grade F, Strong Sell).
What is the price target of In8bio Inc (INAB)?
The analyst target price is $6.25, representing +325.2% upside from the current price of $1.47.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-92.50%
Beta0.04
50D MA$1.61
200D MA$1.95
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—